Merrell Dow Pharmaceuticals

Merrell Pharmaceuticals, Inc.

The Dow Chemical Company

Biomarin Pharmaceutical Inc.

Aventis Pharmaceuticals Inc.

Hoechst Marion Roussel

Microbiotix, Inc.

Mercury Therapeutics, Inc.

Other

Repligen Corporation

Scios Nova, Inc.

Aventis Pharma Limited

Marion Merrell Dow Canada Inc.

Gestion De La Sante Marion Merrell Dow Canada Inc.-marion Merrell Dow Canada Health Management Inc.

Nelsen L. Lentz

Norton P Peet

Joseph P Burkhart

Shyam Sunder

James R Rusche

Michael R Angelastro

Vincent Jacques

Jasbir Singh

Nelsen L Lentz

Shujaath Mehdi

David R Borcherding

Jennifer A Dumont

J O'Neal Johnston

Robert A Farr

Cynthia A Gates

John D Williams

Philippe Bey

Alan J Bitonti

Alan D Cardin

Hwa-Ok Kim

Patrick Shum

John K Daniel

Michael E Le Tourneau

H Randall Munson, Jr

Catherine A Alexander

J O'neal Johnston

Michael J Mullins

Philip M Weintraub

Mark W Dudley

Paul S Wright

Robert J Cregge

Allen T Hopper

Arnab Basu

Donald T Moir

Sharanappa B Rajur

Debra M Mills

John J Weidner

Daniel Aiello

Neal C Birnberg

Hong Liu

Qing Ping Weng

Paresh D Salgaonkar

Pan Yin

Haibo Shang

H Randall Munson

William Jack Kruper, Jr

Donald Paul Matthews

Ray E Drumright

Barbara Cordell

Sai P Sunkara

William J Kruper

Bing Li

Viviane Van Dorsselaer

Robert J Broersma

William A Fordyce

Daniel G Schirlin

Michael John Janusz

Terry L Bowlin

Niall S Doherty

Anna P Vinogradoff

William Arthur Metz, Jr

Timothy Thomas Curran

Mohinder S Kang

Jeffrey N Higaki

Timothy T Curran

Matthew C Torhan

Steven L Gallion

Nelson L Lentz

William A Metz Jr

Janice M Hitchcock

Stephen M Sorensen

Matthew D Linnik

Philip R Kastner

J Anthony Malikayl

Matthew Torhan

Cynthia P Gates

Patrich Wk Shum

Patrick Wk Shum

J Antony Malikayl

Stephen M Sorenson

Allan D Cardin

J O Johnston

Daniel Schirlin

This invention relates to generally inhibiting histone deacetylase ('HDAC') enzymes (e.g., HDAC1, HDAC2, and HDAC3).

Histone deacetylase inhibitors

The compounds provided herein are phenyl analine amides and are useful for inhibiting histone deacteylase ('HDAC') enzymes, such as HDAC1, HDAC2, and HDAC3.

This invention relates to compounds of Formula (I) wherein Cy, L, Y, R, L, and Ar2 are defined herein, for the treatment of cancers, inflammatory disorders, and neurological conditions. 

Compositions including 6-aminohexanoic acid derivatives as HDAC inhibitors

This invention relates to generally inhibiting histone deacetylase (HDAC) enzymes (e.g., HDAC1, HDAC2, and HDAC3).

Organic compounds showing the ability to inhibit effector toxin secretion or translocation mediated by bacterial type III secretion systems are disclosed. The disclosed type III secretion system inhibitor compounds are useful for combating infections by Gram-negative bacteria such asspp.,spp.,spp., en tero pathogenic and enteroinvasivecoli, andspp. having such type III secretion systems.

Inhibitors of bacterial type III secretion system

This invention relates to compounds of Formula (I) wherein Cy, L, Y, R, L, and Arare defined herein, for the treatment of cancers, inflammatory disorders, and neurological conditions. 

The present invention is related to the development of compounds and methods for inhibiting viral infection in a mammal. A pseudotype virus was developed for use in a high throughput assay for identifying nonpeptidic small molecule inhibitors that prevent viral entry into a host cell.

Inhibitors of viral entry into mammalian cells

Organic compounds showing the ability to inhibit viral glycoprotein (GP)-mediated entry of a filovirus into a host cell are disclosed. The disclosed filovirus entry inhibitor compounds are useful for treating, preventing, or reducing the spread of infections by filovirus including the type species Marburg virus (MARV) and Ebola virus (EBOV). Preferred inhibitors of the invention provide therapeutic agents for combating the Ivory Coast, Sudan, Zaire, Bundibugyo, and Reston Ebola virus strains.

Inhibitors of filovirus entry into host cells

The present invention relates to compounds and pharmaceutically acceptable salts, esters and prodrugs of Formula (I) or (II): which are useful as AMPK modulators effective in treating diabetes, obesity and cancer in a subject.

AMPK modulators

This invention relates to generally inhibiting histone deacetylase ('HDAC') enzymes (e.g., HDAC1, HDAC2, and HDAC3) using compounds of formula (I), wherein the substituents are as defined herein.

Growing community of inventors

Cincinnati, OH, United States of America

Norton P Peet